1 / 14

Seasonal and Pandemic Influenza Research Activities National Vaccine Advisory Committee Meeting

Seasonal and Pandemic Influenza Research Activities National Vaccine Advisory Committee Meeting September 27, 2006 Barbara L. Mulach, Ph.D. National Institute of Allergy and Infectious Diseases NIH/DHHS. NIAID Centers of Excellence for Influenza Research and Surveillance.

marcie
Télécharger la présentation

Seasonal and Pandemic Influenza Research Activities National Vaccine Advisory Committee Meeting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Seasonal and Pandemic Influenza Research Activities National Vaccine Advisory Committee Meeting September 27, 2006 Barbara L. Mulach, Ph.D. National Institute of Allergy and Infectious Diseases NIH/DHHS

  2. NIAID Centers of Excellence for Influenza Research and Surveillance Goal: To carry out an international and/or domestic animal surveillance program with emphasis on the rapid characterization of influenza viruses with pandemic potential; to carry out a research program to determine the factors that influence influenza viruses, and characterize the immune response to influenza infection and/or vaccination. • BAA was announced October 18, 2005 • Applications were due March 6, 2006 • Review is ongoing • Awards anticipated in December 2006

  3. NIAID Influenza Diagnostics-Examples Emerging Diagnostic Technologies Advanced/Later Stage Product Development Applied/Early Stage Product Dev Proteomics/Protein Diagnostic Arrays Nanotechnology Multiplex PCR Detection Platform for Respiratory Viruses DNA/RNA Multiplex Platform/Chip for Influenza Detection and Subtyping Multiplex Immunoassay Platform for Respiratory Viruses Multiplex PCR-Mass Spectrometry Platform for Respiratory Viruses

  4. H5N1 Vaccine Trials: Strategies to Enhance Immunogenicity • Route: ID vs. IM administration • Give a 3rd dose of vaccine at 6 months • Adult study completed • Evaluate adjuvants • H5N1 (sanofi) with and without AlOH • H5N1 (Novartis) with and without AlOH or MF59 • H5N1 (Baxter-cell culture) with and without AlOH

More Related